• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Mcmeans Shaun D was granted 1,000 shares, increasing direct ownership by 10% to 10,570 units

    12/13/22 5:39:26 PM ET
    $HTGM
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $HTGM alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    McMeans Shaun D

    (Last) (First) (Middle)
    C/O HTG MOLECULAR DIAGNOSTICS, INC.
    3430 E. GLOBAL LOOP

    (Street)
    TUCSON AZ 85706

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    HTG MOLECULAR DIAGNOSTICS, INC [ HTGM ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    SVP, Finance & Admin. & CFO
    3. Date of Earliest Transaction (Month/Day/Year)
    12/09/2022
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 12/09/2022 A(1) V 1,000(1) A $0.425 10,570 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. This Form 4 is being filed voluntarily to report the acquisition of 1,000 shares by the Reporting Person on December 9, 2022 pursuant to the Issuer's Employee Stock Purchase Plan.
    Remarks:
    /s/ Shaun D. McMeans 12/13/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $HTGM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $HTGM

    DatePrice TargetRatingAnalyst
    1/7/2022$5.00 → $8.00Hold → Buy
    Craig-Hallum
    More analyst ratings

    $HTGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Barat Stephen

      4 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)

      6/9/23 8:11:23 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Barat Stephen

      4 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)

      4/7/23 4:16:01 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 3: New insider Barat Stephen claimed ownership of 1,361 shares

      3 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)

      2/10/23 4:34:09 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HTGM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HTG to Highlight the Advantages of its Drug Discovery Engine at the 2023 BIO International Convention

      TUCSON, Ariz., May 18, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced that its management team will present the advantages of its proprietary drug discovery engine at the 2023 Biotechnology Innovation Organization (BIO) International Convention and will host in-person meetings during the remaining days of the June 5 – 8, 2023 event in Boston, MA. HTG is pioneering a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. HTG's objective is to develop best-in-class molecules for the treat

      5/18/23 8:00:00 AM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • HTG Highlights the Advantages of Its Drug Discovery Engine

      TUCSON, Ariz., May 16, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported achievement of another technical milestone in its drug discovery business. HTG is pioneering a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. HTG's objective is to develop best-in-class molecules for the treatment of diseases, with the ability to apply its platform agnostically across therapy areas. At the center of this approach is HTG's proprietary RNA profiling technologies, functionally married with an adva

      5/16/23 8:47:40 AM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • HTG Molecular Diagnostics Reports First Quarter 2023 Results and Provides Recent Business Highlights

      TUCSON, Ariz., May 10, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported financial results for the quarter ended March 31, 2023 and provided recent drug discovery business highlights. HTG has pioneered a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. At the center of this approach is the application of HTG's proprietary RNA profiling technologies, functionally married with advanced medicinal chemistry using a novel artificial intelligence ("AI")-driven platform. This unique drug can

      5/10/23 5:51:27 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HTGM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HTG Molecular Diagnostics upgraded by Craig-Hallum with a new price target

      Craig-Hallum upgraded HTG Molecular Diagnostics from Hold to Buy and set a new price target of $8.00 from $5.00 previously

      1/7/22 10:15:02 AM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SVB Leerink reiterated coverage on HTG Molecular Diagnostics with a new price target

      SVB Leerink reiterated coverage of HTG Molecular Diagnostics with a rating of Outperform and set a new price target of $10.00 from $15.00 previously

      5/14/21 6:42:26 AM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • HC Wainwright & Co. reiterated coverage on HTG Molecular Diagnostics with a new price target

      HC Wainwright & Co. reiterated coverage of HTG Molecular Diagnostics with a rating of Buy and set a new price target of $9.00 from $11.00 previously

      5/14/21 6:28:53 AM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HTGM
    SEC Filings

    See more
    • HTG Molecular Diagnostics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)

      6/8/23 4:51:32 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • HTG Molecular Diagnostics Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Leadership Update

      8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)

      6/5/23 3:42:54 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • HTG Molecular Diagnostics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)

      5/24/23 5:01:07 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HTGM
    Financials

    Live finance-specific insights

    See more
    • HTG Announces Certain Preliminary 2022 Unaudited Financial Results

      Preliminary full year 2022 unaudited revenue of $6.4 million Cash and cash equivalents of $12.2 million as of December 31, 2022 TUCSON, Ariz., Jan. 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced certain preliminary, unaudited financial results for the year ended December 31, 2022. Total revenue for the full year 2022 is expected to be approximately $6.4 million, including approximately $2.7 million of HTG Transcriptome Panel (HTP) revenue representing 42% of our total revenue. Cash and cash

      1/6/23 8:00:00 AM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • HTG Molecular Diagnostics Reports Second Quarter 2022 Results

      TUCSON, Ariz., Aug. 11, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported recent business highlights and financial results for the quarter ended June 30, 2022. Throughout the quarter ended June 30, 2022, the Company's technology and strategic development efforts were highlighted in a number of customer and KOL presentations and publications including, but not limited to, the following: A webinar titled "Integration of the HTG Transcriptome Panel into Preclinical and Clinical Programs to Drive Precision Medicine Research" fe

      8/11/22 4:05:00 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • HTG Molecular Diagnostics to Announce Q2 2022 Financial Results and Host Conference Call on Thursday, August 11

      TUCSON, Ariz., Aug. 04, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that it will report its financial results for the quarter ended June 30, 2022 after the market close on Thursday, August 11, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time. Details for the conference call are as follows: Conference Call & Webcast Details Date:Thursday, August 11Time:4:30pm ETToll Free:1-800-954-0602 International:1-212-231-2936 Conference ID:2

      8/4/22 8:00:00 AM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HTGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by HTG Molecular Diagnostics Inc. (Amendment)

      SC 13G/A - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)

      2/13/23 3:33:23 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by HTG Molecular Diagnostics Inc. (Amendment)

      SC 13G/A - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)

      2/10/23 9:03:52 AM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by HTG Molecular Diagnostics Inc.

      SC 13G - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)

      2/3/23 4:02:18 PM ET
      $HTGM
      Biotechnology: Laboratory Analytical Instruments
      Industrials